Rituximab biosimilar (Shanghai CP Guojian Pharmaceutical)

利妥昔单抗生物类似药 (Shanghai CP Guojian Pharmaceutical)

Report date: 2024/12/25 20:00:50

Base Information

Drug NameRituximab biosimilar (Shanghai CP Guojian Pharmaceutical)

Drug Alias Name利妥昔单抗生物仿制药 (Shanghai CP Guojian Pharmaceutical)Retuxira健妥昔CMAB-304304R

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (NDA/BLA)

Highest Status in ChinaDiscontinued

Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Other Information

ATC CodeL01XC02